Wells Fargo
GPCR icon

Wells Fargo’s Structure Therapeutics GPCR Stock Holding History

Wells Fargo’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$558K Buy
10,398
+2,580
+33% +$114K ﹤0.01% 4534
2026
Q1 		$377K Buy
7,818
+2,154
+38% +$147K ﹤0.01% 4307
2025
Q4 		$394K Sell
5,664
-394
-7% -$16.1K ﹤0.01% 4653
2025
Q3 		$170K Sell
6,058
-1,165
-16% -$23.2K ﹤0.01% 5020
2025
Q2 		$150K Sell
7,223
-122
-2% -$2.68K ﹤0.01% 4936
2025
Q1 		$127K Sell
7,345
-2,758
-27% -$67.6K ﹤0.01% 4972
2024
Q4 		$274K Buy
10,103
+6,763
+202% +$240K ﹤0.01% 4592
2024
Q3 		$147K Buy
3,340
+2,606
+355% +$101K ﹤0.01% 4778
2024
Q2 		$28.8K Buy
734
+288
+65% +$11.8K ﹤0.01% 5478
2024
Q1 		$19.1K Sell
446
-280
-39% -$11.8K ﹤0.01% 5590
2023
Q4 		$29.6K Buy
+726
New +$41.6K ﹤0.01% 5482

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wells Fargo's GPCR Position: Q2 2026 in Review

Wells Fargo increased its Structure Therapeutics (GPCR) stake by 33% in Q2 2026, buying an estimated $114K and bringing the position to 10,398 shares worth $558K. The position accounts for ﹤0.01% of the portfolio, ranked #4534.

Wells Fargo first reported a position in GPCR in Q4 2023 and has held it in 11 quarters since. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Wells Fargo held 10,398 shares of Structure Therapeutics worth $558K as of Q2 2026.
  • Wells Fargo bought 2,580 Structure Therapeutics shares in Q2 2026, an estimated $114K.
  • Structure Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4534 holding.
  • Wells Fargo first reported a position in Structure Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.